Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function.
until further notice
SourceHuman Molecular Genetics, 19, R1, (2010), pp. R90-7
Article / Letter to editor
Display more detailsDisplay less details
Cell Biology (UMC)
Human Molecular Genetics
SubjectDCN 2: Functional Neurogenomics; IGMD 8: Mitochondrial medicine; NCMLS 4: Energy and redox metabolism
Myotonic dystrophy (DM) is a complex, dominantly inherited, multisystem disorder and the archetypal example of an RNA gain-of-function disease. Unstable expansions of (CTG*CAG)n or (CCTG*CAGG)n repeat tracts in the DMPK and ZNF9 genes cause the two known subtypes of myotonic dystrophy, DM1 and DM2, for which no cure or effective molecular treatment exists. Focus in therapeutic development is currently on toxic, expanded (C/CUG)n RNAs. A series of recent papers provide proof of concept of promising strategies using antisense oligonucleotides or small organic compounds aimed at either complete elimination of expanded (CUG)n RNA transcripts or prevention of detrimental protein binding to thermodynamically stable (C/CUG)n hairpin structures. These developments offer new hope to patients with DM, even though several hurdles still have to be overcome before they can be introduced into clinical practice.
Upload full text
Use your RU credentials (u/z-number and password) tolog in with SURFconextto upload a file for processing by the repository team.